Strides Arcolab ties up with Eli Lilly for cancer drug

Strides Arcolab ties up with Eli Lilly for cancer drugBangalore-based Strides Arcolab has said that it is entering into a partnership with global pharmaceutical major Eli Lilly and Co for expanding delivery of cancer medicines in emerging countries.

Under the agreement, Lilly will in-license a portfolio of branded generic injectable and oral cancer medicines from Agila Specialties, which is a unit of Strides Arcolab. Agila Specialties will be responsible for manufacturing cancer medicines and Lilly will register and market the drugs in several countries across the world.

The agreement currently covers 10 medicines but Lilly might be able to add additional branded generic oncology products to its portfolio offering in several countries. The partnership will allow Arcolab to benefit from the stong presence of Lilly across various countries and on the other hand will allow Lilly to have a presence in the Indian cancer drug segment.

Melt Van Der Spuy, Managing Director, Lilly India said, "This strategic partnership marks Lilly India's entry into branded generics, reaffirming our commitment to reach more Indian patients. We believe this partnership will help us build a significantly larger and more meaningful presence in the Indian cancer segment, and hence, enable us to better serve many more Indian patients suffering from various forms of cancer."

Arun Kumar, Founder & Group CEO of Strides Arcolab expressed delight over the partnership and said that the products will benefit from Lilly's strong global presence across several emerging markets.